My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 527

    1.

    Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1.

    Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL, McGuinness OP, Wasserman DH, Vaughan DE, Fogo AB.

    Diabetes. 2004 Feb;53(2):336-46.PMID: 14747283 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Peroxisome proliferator-activated receptor-alpha deficiency does not alter insulin sensitivity in mice maintained on regular or high-fat diet: hyperinsulinemic-euglycemic clamp studies.

    Haluzik M, Gavrilova O, LeRoith D.

    Endocrinology. 2004 Apr;145(4):1662-7. Epub 2003 Dec 11.PMID: 14670996 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity.

    Morange PE, Lijnen HR, Alessi MC, Kopp F, Collen D, Juhan-Vague I.

    Arterioscler Thromb Vasc Biol. 2000 Apr;20(4):1150-4.PMID: 10764686 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Plasminogen activator inhibitor-1 modulates adipocyte differentiation.

    Liang X, Kanjanabuch T, Mao SL, Hao CM, Tang YW, Declerck PJ, Hasty AH, Wasserman DH, Fogo AB, Ma LJ.

    Am J Physiol Endocrinol Metab. 2006 Jan;290(1):E103-E113. Epub 2005 Sep 6.PMID: 16144810 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels.

    Haluzik MM, Lacinova Z, Dolinkova M, Haluzikova D, Housa D, Horinek A, Vernerova Z, Kumstyrova T, Haluzik M.

    Endocrinology. 2006 Sep;147(9):4517-24. Epub 2006 Jun 1.PMID: 16740970 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice.

    Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, Walker BR, Flier JS, Mullins JJ, Seckl JR.

    Diabetes. 2004 Apr;53(4):931-8.PMID: 15047607 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic and Type 2 diabetic subjects.

    Koistinen HA, Dusserre E, Ebeling P, Vallier P, Koivisto VA, Vidal H.

    Diabetes Metab Res Rev. 2000 Sep-Oct;16(5):364-9.PMID: 11025560 [PubMed - indexed for MEDLINE]Related articles

    8.

    Reduced adiposity in bitter melon (Momordica charantia)-fed rats is associated with increased lipid oxidative enzyme activities and uncoupling protein expression.

    Chan LL, Chen Q, Go AG, Lam EK, Li ET.

    J Nutr. 2005 Nov;135(11):2517-23.PMID: 16251604 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Resistance to high-fat diet-induced obesity but exacerbated insulin resistance in mice overexpressing preadipocyte factor-1 (Pref-1): a new model of partial lipodystrophy.

    Villena JA, Choi CS, Wang Y, Kim S, Hwang YJ, Kim YB, Cline G, Shulman GI, Sul HS.

    Diabetes. 2008 Dec;57(12):3258-66. Epub 2008 Oct 3.PMID: 18835937 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice.

    Klaman LD, Boss O, Peroni OD, Kim JK, Martino JL, Zabolotny JM, Moghal N, Lubkin M, Kim YB, Sharpe AH, Stricker-Krongrad A, Shulman GI, Neel BG, Kahn BB.

    Mol Cell Biol. 2000 Aug;20(15):5479-89.PMID: 10891488 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Effect of plasminogen activator inhibitor-1 deficiency on nutritionally-induced obesity in mice.

    Lijnen HR.

    Thromb Haemost. 2005 May;93(5):816-9.PMID: 15886793 [PubMed - indexed for MEDLINE]Related articles

    12.

    Circulating resistin in lean, obese, and insulin-resistant mouse models: lack of association with insulinemia and glycemia.

    Lee JH, Bullen JW Jr, Stoyneva VL, Mantzoros CS.

    Am J Physiol Endocrinol Metab. 2005 Mar;288(3):E625-32. Epub 2004 Nov 2.PMID: 15522996 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Skeletal muscle-specific deletion of lipoprotein lipase enhances insulin signaling in skeletal muscle but causes insulin resistance in liver and other tissues.

    Wang H, Knaub LA, Jensen DR, Young Jung D, Hong EG, Ko HJ, Coates AM, Goldberg IJ, de la Houssaye BA, Janssen RC, McCurdy CE, Rahman SM, Soo Choi C, Shulman GI, Kim JK, Friedman JE, Eckel RH.

    Diabetes. 2009 Jan;58(1):116-24. Epub 2008 Oct 24.PMID: 18952837 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Nuclear receptors as targets for drug development: molecular mechanisms for regulation of obesity and insulin resistance by peroxisome proliferator-activated receptor gamma, CREB-binding protein, and adiponectin.

    Tsuchida A, Yamauchi T, Kadowaki T.

    J Pharmacol Sci. 2005 Feb;97(2):164-70. Epub 2005 Feb 11. Review.PMID: 15725703 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Androgen receptor null male mice develop late-onset obesity caused by decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion.

    Fan W, Yanase T, Nomura M, Okabe T, Goto K, Sato T, Kawano H, Kato S, Nawata H.

    Diabetes. 2005 Apr;54(4):1000-8.PMID: 15793238 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1.

    Shah C, Yang G, Lee I, Bielawski J, Hannun YA, Samad F.

    J Biol Chem. 2008 May 16;283(20):13538-48. Epub 2008 Mar 22.PMID: 18359942 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-gamma agonism.

    Dallaire P, Bellmann K, Laplante M, Gélinas S, Centeno-Baez C, Penfornis P, Peyot ML, Latour MG, Lamontagne J, Trujillo ME, Scherer PE, Prentki M, Deshaies Y, Marette A.

    Diabetes. 2008 Aug;57(8):1999-2011. Epub 2008 May 5.PMID: 18458147 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Bone marrow plasminogen activator inhibitor-1 influences the development of obesity.

    De Taeye BM, Novitskaya T, Gleaves L, Covington JW, Vaughan DE.

    J Biol Chem. 2006 Oct 27;281(43):32796-805. Epub 2006 Aug 23.PMID: 16931518 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Peripheral, but not central, administration of adiponectin reduces visceral adiposity and upregulates the expression of uncoupling protein in agouti yellow (Ay/a) obese mice.

    Masaki T, Chiba S, Yasuda T, Tsubone T, Kakuma T, Shimomura I, Funahashi T, Matsuzawa Y, Yoshimatsu H.

    Diabetes. 2003 Sep;52(9):2266-73.PMID: 12941765 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Activation of the hexosamine signaling pathway in adipose tissue results in decreased serum adiponectin and skeletal muscle insulin resistance.

    Hazel M, Cooksey RC, Jones D, Parker G, Neidigh JL, Witherbee B, Gulve EA, McClain DA.

    Endocrinology. 2004 May;145(5):2118-28. Epub 2003 Dec 18.PMID: 14684615 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity